SMC
NVO

Smith, Moore & Co’s Novo Nordisk NVO Stock Holding History

Smith, Moore & Co’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-2,933
Closed -$202K – 541
2025
Q2 		$202K Buy
+2,933
New +$200K 0.02% 494
2024
Q4 		– Sell
-2,761
Closed -$329K – 497
2024
Q3 		$329K Sell
2,761
-1,338
-33% -$178K 0.03% 345
2024
Q2 		$585K Buy
4,099
+184
+5% +$24.4K 0.06% 244
2024
Q1 		$503K Buy
3,915
+215
+6% +$25.6K 0.05% 268
2023
Q4 		$383K Buy
3,700
+700
+23% +$69.2K 0.05% 292
2023
Q3 		$273K Buy
+3,000
New +$264K 0.04% 321

Other funds holding NVO

Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return
Fayez Sarofim & Co
Fayez Sarofim & Co Houston, Texas $39.1B AUM 15.14% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Smith, Moore & Co's NVO Position: Q3 2025 in Review

Smith, Moore & Co sold out of Novo Nordisk (NVO) in Q3 2025, closing a stake of 2,933 shares — an estimated $202K sold.

Smith, Moore & Co first reported a position in NVO in Q3 2023 and held it in 6 quarters. The position peaked at $585K in Q2 2024. 1,395 funds tracked by Wall St. Rank hold NVO as of Q3 2025.

  • Smith, Moore & Co reported no remaining Novo Nordisk position as of Q3 2025 after selling out during the quarter.
  • Smith, Moore & Co sold 2,933 Novo Nordisk shares in Q3 2025, an estimated $202K.
  • Smith, Moore & Co first reported a position in Novo Nordisk in Q3 2023 and held it in 6 quarters.
  • Smith, Moore & Co's Novo Nordisk position peaked at $585K in Q2 2024.
  • 1,395 funds tracked by Wall St. Rank held Novo Nordisk as of Q3 2025.

Based on Smith, Moore & Co's 13F filing for Q3 2025, filed 12 Nov 2025.